ArticleFrontiers in public health2022
Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
Hao Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it